Male Infertility and Azoospermia

Male infertility in dogs and cats is defined as the inability to achieve a pregnancy in a fertile female after appropriate mating or artificial insemination during the optimal breeding period. Azoospermia, a specific form of male infertility, is the complete absence of spermatozoa in the ejaculate. This condition can be classified as pre-testicular (endocrine or systemic), testicular (primary testicular failure), or post-testicular (obstruction or ejaculatory dysfunction). In theriogenology, a thorough evaluation of the male reproductive tract, semen quality, and endocrine status is essential to differentiate these categories. Azoospermia must be distinguished from aspermia (lack of ejaculate) and oligozoospermia (low sperm count). The condition may be permanent or transient, depending on the underlying etiology. In breeding animals, azoospermia has significant economic and genetic implications, necessitating a systematic diagnostic approach and evidence-based management.

The etiologies of male infertility and azoospermia are diverse and can be categorized into pre-testicular, testicular, and post-testicular causes. Pre-testicular causes include endocrine imbalances such as hypothyroidism, hyperadrenocorticism, and hypogonadotropic hypogonadism, often due to pituitary or hypothalamic lesions. Exogenous androgen administration (e.g., anabolic steroids) suppresses gonadotropin release, leading to testicular atrophy. Testicular causes include congenital anomalies (e.g., testicular hypoplasia, cryptorchidism), chromosomal abnormalities (e.g., XX male syndrome), infectious orchitis (e.g., Brucella canis, Ehrlichia canis, Leishmania infantum), immune-mediated orchitis, trauma, neoplasia (e.g., Sertoli cell tumor, seminoma), and toxic insults (e.g., chemotherapy, radiation, certain drugs like ketoconazole). Post-testicular causes involve obstruction of the epididymis or ductus deferens due to congenital aplasia, segmental aplasia, or acquired inflammation (e.g., epididymitis, prostatitis). Retrograde ejaculation and ejaculatory dysfunction (e.g., neuromuscular disorders, prostatic disease) can also result in azoospermia. In cats, similar etiologies are observed, with feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) infections potentially causing testicular degeneration.

Male infertility and azoospermia are relatively uncommon in canine and feline practice but are significant in breeding programs. The prevalence of azoospermia in dogs is estimated to be less than 5% of all infertile males, but it may be higher in certain breeds with hereditary predispositions. Breeds such as the German Shepherd Dog, Boxer, and Golden Retriever have been reported to have higher incidences of testicular tumors and cryptorchidism, which can lead to infertility. Age is a factor, with older males more likely to develop testicular neoplasia or prostatic disease. In cats, the prevalence is lower due to less intensive breeding management, but purebred cats may have higher risks of inherited conditions. Environmental factors, such as heat stress, poor nutrition, and iatrogenic causes (e.g., corticosteroid therapy), can also contribute. The economic impact is substantial in stud dogs and toms, where infertility leads to loss of breeding income and genetic value.

The pathophysiology of azoospermia involves disruption of spermatogenesis, sperm transport, or ejaculation. Pre-testicular causes lead to reduced gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, and subsequent Leydig cell dysfunction (low testosterone) and Sertoli cell dysfunction (impaired spermatogenesis). Testicular causes directly damage the seminiferous epithelium, leading to germ cell depletion, Sertoli cell-only syndrome, or fibrosis. Infectious agents like Brucella canis cause granulomatous inflammation and tubular destruction. Post-testicular obstruction prevents sperm from entering the ejaculate, while epididymal dysfunction impairs sperm maturation and storage. In cases of retrograde ejaculation, sperm are ejaculated into the bladder. Endocrine feedback mechanisms are disrupted, with inhibin levels decreasing and FSH levels rising in primary testicular failure. This hormonal profile helps differentiate testicular from pre-testicular causes.

Predisposing factors for male infertility and azoospermia include breed-specific genetic predispositions (e.g., cryptorchidism in Boxers, testicular tumors in German Shepherds), advanced age, and congenital anomalies. Environmental factors such as heat stress, poor nutrition, and exposure to toxins (e.g., pesticides, heavy metals) can impair spermatogenesis. Iatrogenic factors include the use of anabolic steroids, glucocorticoids, and certain antibiotics (e.g., chloramphenicol). Systemic diseases like hypothyroidism, diabetes mellitus, and chronic renal failure can affect reproductive function. Stress, whether physical or psychological, can suppress the hypothalamic-pituitary-gonadal axis. In breeding management, overuse of stud dogs (frequent ejaculation) can lead to temporary azoospermia, while prolonged sexual rest can cause sperm accumulation and decreased motility. In cats, obesity and poor dental health have been associated with reduced fertility.

Clinical signs of male infertility and azoospermia are often subtle and may go unnoticed until breeding fails. The primary sign is failure to conceive after multiple matings or artificial inseminations. Physical examination may reveal testicular atrophy or asymmetry, cryptorchidism, scrotal dermatitis, or prostatic enlargement. In cases of orchitis, there may be pain, swelling, and fever. Behavioral changes such as decreased libido or aggression may be observed. In some cases, there are no overt clinical signs, and the condition is only detected during semen evaluation. Azoospermia is confirmed by the absence of spermatozoa in the ejaculate, but the ejaculate may appear normal in volume and color. In cases of retrograde ejaculation, urine may contain spermatozoa. Systemic signs of underlying diseases (e.g., hypothyroidism, hyperadrenocorticism) may also be present.

Differential diagnoses for azoospermia include: 1) Aspermia (lack of ejaculate) due to ejaculatory dysfunction or prostatic disease; 2) Oligozoospermia (low sperm count) which may be transient; 3) Retrograde ejaculation, where sperm are present in urine; 4) Testicular neoplasia (e.g., Sertoli cell tumor, seminoma) causing hormonal imbalances; 5) Cryptorchidism, where the retained testicle may produce hormones but not sperm; 6) Orchitis/epididymitis due to infectious agents; 7) Hypothyroidism, which can cause decreased libido and spermatogenic dysfunction; 8) Hyperadrenocorticism, which suppresses gonadotropins; 9) Congenital abnormalities such as segmental aplasia of the epididymis; 10) Immune-mediated orchitis. Each differential can be ruled in or out based on history, physical exam, semen analysis, endocrine testing, and imaging.

The diagnostic algorithm for azoospermia begins with a thorough history and physical examination, including testicular palpation and prostatic evaluation. Semen collection via digital manipulation or electroejaculation is performed, and the ejaculate is evaluated for volume, sperm concentration, motility, and morphology. If azoospermia is confirmed, a urine sample is collected after ejaculation to check for retrograde ejaculation. Endocrine testing includes serum testosterone, LH, FSH, and inhibin concentrations. Low testosterone with low LH/FSH suggests pre-testicular causes; high FSH with low inhibin indicates testicular failure. Thyroid and adrenal function tests are performed if endocrinopathy is suspected. Ultrasonography of the testes, epididymides, and prostate is used to identify structural abnormalities. Testicular biopsy may be indicated for definitive diagnosis of testicular degeneration or neoplasia. Genetic testing for chromosomal abnormalities is recommended in purebred animals. Brucella canis serology and PCR are essential in endemic areas.

Laboratory findings in azoospermia depend on the underlying cause. In primary testicular failure, serum FSH is elevated (>2-3 times normal), inhibin is decreased, and testosterone may be low or normal. In pre-testicular causes, LH and FSH are low or normal, and testosterone is low. Semen analysis reveals no spermatozoa, but the seminal fluid may have normal or altered pH and fructose levels. Urinalysis after ejaculation may show spermatozoa in retrograde ejaculation. Hematology and biochemistry may reveal abnormalities associated with systemic diseases (e.g., hypercholesterolemia in hypothyroidism, elevated cortisol in hyperadrenocorticism). Brucella canis serology (rapid slide agglutination test, agar gel immunodiffusion) and PCR are positive in infectious orchitis. Testicular biopsy histopathology shows germ cell aplasia, maturation arrest, or fibrosis.

Ultrasonography of the testes is a key imaging modality. In azoospermia, the testes may appear small, hyperechoic, or have cystic lesions. Testicular tumors appear as hypoechoic masses. The epididymides can be evaluated for cysts or obstruction. Prostatic ultrasonography may reveal prostatitis or cysts. Radiography is less useful but can detect testicular mineralization or prostatic enlargement. In cases of cryptorchidism, abdominal ultrasonography or CT may be needed to locate the retained testicle. MRI is rarely used but can provide detailed images of the pituitary gland in suspected hypogonadotropic hypogonadism.

Cytology of fine-needle aspirates of testicular masses can help diagnose neoplasia (e.g., Sertoli cell tumors, seminomas). Histopathology of testicular biopsies is the gold standard for evaluating spermatogenesis. Findings include hypospermatogenesis, maturation arrest, Sertoli cell-only syndrome, and tubular fibrosis. Special stains (e.g., periodic acid-Schiff) can highlight basement membrane thickening. In orchitis, inflammatory infiltrates (lymphocytes, plasma cells, neutrophils) are seen. Immunohistochemistry may be used to differentiate tumor types.

Treatment of azoospermia depends on the underlying cause. For pre-testicular causes, addressing the primary endocrinopathy (e.g., thyroid hormone supplementation for hypothyroidism, trilostane for hyperadrenocorticism) may restore fertility. Discontinuation of exogenous steroids is essential. For infectious orchitis, appropriate antibiotics (e.g., doxycycline for Brucella canis, but prognosis is poor) are used. Testicular neoplasia requires surgical castration. For obstructive azoospermia, surgical correction (e.g., epididymovasostomy) may be attempted but has a guarded prognosis. In cases of ejaculatory dysfunction, pharmacological agents such as imipramine (2-4 mg/kg PO q12h) or prazosin (0.25-0.5 mg/kg PO q8-12h) may be used to enhance ejaculation. Hormonal therapy with GnRH (e.g., 2 mcg/kg SC q24h for 3-4 weeks) or hCG (500-1000 IU IM q3-4 days for 3-4 weeks) may stimulate spermatogenesis in some cases. However, response is variable. In cases of permanent azoospermia, the animal should be retired from breeding.

The prognosis for azoospermia is guarded to poor, depending on the etiology. Pre-testicular causes may be reversible if the underlying condition is treated early. Testicular causes, especially those involving fibrosis or neoplasia, are often irreversible. Post-testicular obstruction may be surgically correctable, but success rates are low. In cases of infectious orchitis, the prognosis is poor due to permanent testicular damage. The overall fertility potential is determined by the degree of spermatogenic recovery, which can be monitored via serial semen evaluations. If azoospermia persists for more than 6 months, the prognosis for return to fertility is very poor.

Follow-up for azoospermia includes serial semen evaluations every 4-6 weeks to monitor for return of spermatozoa. Endocrine testing (testosterone, FSH, LH) should be repeated to assess response to therapy. Ultrasonography may be used to monitor testicular size and structure. In breeding animals, a breeding soundness examination should be performed before allowing mating. If the animal is treated for an underlying endocrinopathy, regular monitoring of hormone levels is necessary. In cases of surgical intervention, post-operative care and re-evaluation are essential.

Clinical pearls: 1) Always perform a complete semen evaluation, including sperm count, motility, and morphology, before diagnosing azoospermia. 2) Check for retrograde ejaculation by examining urine after ejaculation. 3) Measure FSH and inhibin to differentiate testicular from pre-testicular causes. 4) In cases of cryptorchidism, the retained testicle may produce testosterone but not sperm, so semen analysis is crucial. Pitfalls: 1) Do not diagnose azoospermia based on a single ejaculate; repeat collection is necessary. 2) Avoid using exogenous testosterone for treatment, as it suppresses spermatogenesis. 3) Do not overlook systemic diseases like hypothyroidism. 4) In cases of Brucella canis, the prognosis is poor, and the animal should be removed from breeding due to zoonotic risk.

Current drug protocols for male infertility and azoospermia include: 1) GnRH (e.g., gonadorelin) at 2 mcg/kg SC q24h for 3-4 weeks to stimulate gonadotropin release. 2) hCG at 500-1000 IU IM q3-4 days for 3-4 weeks to stimulate Leydig cells. 3) Imipramine (2-4 mg/kg PO q12h) or prazosin (0.25-0.5 mg/kg PO q8-12h) for ejaculatory dysfunction. 4) For hypothyroidism, levothyroxine at 0.02-0.04 mg/kg PO q12h. 5) For hyperadrenocorticism, trilostane at 2-6 mg/kg PO q24h. 6) Antibiotics for infectious orchitis: doxycycline (5-10 mg/kg PO q12h) for Brucella canis, but treatment is not recommended due to poor prognosis and zoonotic risk. 7) For immune-mediated orchitis, immunosuppressive doses of prednisone (1-2 mg/kg PO q24h) may be tried, but response is poor.

Evidence-based literature on male infertility and azoospermia in dogs and cats is limited. Key studies include: 1) Johnston et al. (2001) in 'Canine and Feline Theriogenology' provide comprehensive guidelines for semen evaluation and diagnosis of azoospermia. 2) England and von Heimendahl (2010) in the BSAVA Manual of Small Animal Reproduction discuss diagnostic approaches and treatment options. 3) A study by Kustritz (2007) reported that testicular biopsy is a valuable diagnostic tool but may have a negative impact on fertility. 4) Research on GnRH therapy has shown variable results, with some dogs responding to treatment. 5) Consensus guidelines from the American College of Theriogenologists (ACT) recommend a systematic approach to male infertility, including endocrine testing and imaging. Overall, the evidence base is weak, and most recommendations are based on expert opinion and extrapolation from other species.